Claims for Patent: 11,643,397

Summary for Patent: 11,643,397

Title:	Prolyl hydroxylase inhibitors
Abstract:	The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
Inventor(s):	Kevin J. Duffy, Duke M. FITCH, Jian Jin, Ronggang Liu, Antony N. Shaw, Kenneth Wiggall
Assignee:	GlaxoSmithKline LLC
Application Number:	US17/383,554
Patent Claims:	1. A compound according to formula (I): wherein: R1 and R4 are each independently selected from the group consisting of hydrogen, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C3-C8cycloalkyl, C3-C8cycloalkyl-C1-C10alkyl, C5-C8cycloalkenyl, C5-C8cycloalkenyl-C1-C10alkyl, C3-C8heterocycloalkyl, C3-C8heterocycloalkyl-C1-C10alkyl, aryl, aryl-C1-C10alkyl, heteroaryl and heteroaryl-C1-C10alkyl; R2 is —OR9; R3 is H; R9 is H or a cation; X is O; and Y is O; where any carbon or heteroatom of R1, and R4 is unsubstituted; and a pharmaceutically acceptable salt thereof. 2. A method of treating anemia in a human in need thereof which comprises administering to such human a therapeutically effective amount of a compound as described in claim 1. 3. A method of treating anemia in a human in need thereof which comprises administering to such human a therapeutically effective amount of N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof. 4. A method of treating anemia in a human in need thereof which comprises administering to such human a therapeutically effective amount of N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine.